Results 71 to 80 of about 7,734 (200)
Journal of Animal Law, Ethics and One HealthOrganoids are multicellular, three-dimensional structures derived from stem cells. They require an extracellular matrix and are capable of recapitulating cell types, organ structure, and organ function.
Inesa Fausch +5 more
doaj +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend New approach methodologies (NAMs) to test the pharmaco‐ and chemicokinetics of compound transfer across the human placental barrier in late pregnancy. Abstract This review addresses an important and timely topic at the intersection of placental biology with respect to barrier transfer kinetics, toxicology and mathematical ...
Paul Brownbill, Eleanor Doman
wiley +1 more source
Limitations and Modifications of Skin Sensitization NAMs for Testing Inorganic Nanomaterials
ToxicsSince 2020, the REACh regulation requires toxicological data on nanoforms of materials, including the assessment of their skin-sensitizing properties.
Britta Wareing +5 more
doaj +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend A summary of the current knowledge around membrane transporter expression in the most widely used in vitro models of human trophoblasts, including primary placental tissue, cancer cell lines and trophoblast stem cells, as well as the techniques to attempt to mimic the human placenta in vivo.
Rhiannon Pass +2 more
wiley +1 more source
Developing an approach for evaluating the cardiotoxic potential of botanicals
Frontiers in ToxicologyBotanicals (e.g., extracts derived from plants, algae, or fungi) are increasingly utilized by consumers with the hope of enhancing their health, managing symptoms, or preventing ailments; however, these products have often had limited pre-market toxicity
Julie Krzykwa +14 more
doaj +1 more source
The Plant Genome, Volume 19, Issue 4, December 2026.Abstract Complex agronomic traits in rice (Oryza sativa L.) are controlled by many genetic loci; however, dissection is often constrained in biparental mapping populations by limited recombination and narrow genetic diversity, and in diversity sets by spurious associations arising from cryptic relatedness.
Fergie Ann Quilloy +6 more
wiley +1 more source
Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?
Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1169-1172, November 2026.Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental ...
Gilbert J. Burckart +6 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1368-1378, November 2026.Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer +9 more
wiley +1 more source
Application of New Approach Methodologies to Improve Oral Biopharmaceutic Assessments
PharmaceuticsBackground/Objectives: The rapid expansion of New Approach Methodologies (NAMs) is transforming oral biopharmaceutics by offering mechanistically rich, human-relevant tools that can reduce reliance on animal testing while improving translational ...
Mauricio A. García +4 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1281-1286, November 2026.Tuberculosis remains an urgent global health crisis that requires an accelerated development of novel regimens. Rodent and rabbit studies currently inform early translational predictions. However, the zebrafish (Danio rerio) embryo/larva, as a New Approach Methodology, provides an ethical, cost‐effective, and high‐throughput non‐mammalian disease model
Bart van Lieshout +3 more
wiley +1 more source